Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
Mustang Bio Inc
Mustang Bio Inc logo

MBIO - Mustang Bio Inc Reuters News

$3.12 0.0  0.0%

Last Trade - 04/03/21

Sector
Healthcare
RiskRating
Speculative
Size
Small Cap
Style
Sucker Stock
Market Cap £146.5m
Enterprise Value £92.3m
Revenue £n/a
Position in Universe 4380th / 6647
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions MBIO Dividends
Reuters News
All News Reuters News Company Announcements
Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences
Thu 1:00pm News
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
26th Feb News
BRIEF-Mustang Bio Provides Updates On Its Lentiviral Gene Therapies For The Treatment Of X-Linked Severe Combined Immunodeficiency
2nd Feb News
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
2nd Feb News
Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
5th Jan News
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
21st Dec '20 News
BRIEF-Mustang Bio Announces Interim Phase 1/2 Data For MB-106 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
7th Dec '20 News
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
7th Dec '20 News
BRIEF-Mustang Bio Files Prospectus Supplement Related To Common Stock Offering Of Up To $100 Million
4th Dec '20 News
Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
1st Dec '20 News
BRIEF-Mustang Bio Announces Positive Opinion From The European Medicines Agency On Orphan Drug Designation For Its Lentiviral Gene Therapy For The Treatment Of X-Linked Severe Combined Immunodeficiency
24th Nov '20 News
Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
24th Nov '20 News
Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
23rd Nov '20 News
BRIEF-Mustang Bio Reports Third Quarter 2020 Financial Results And Recent Corporate Highlights
6th Nov '20 News
Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
6th Nov '20 News
BRIEF-Mustang Bio Announces Mb-106 Data Selected For Presentation At The 62Nd American Society Of Hematology (Ash) Annual Meeting
4th Nov '20 News
Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
4th Nov '20 News
BRIEF-Mustang Bio Announces Initial Phase 1 Data On MB-105 For Patients With PSCA-Positive Castration Resistant Prostate Cancer
26th Oct '20 News
Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer
26th Oct '20 News
BRIEF-Mustang Bio Inc Files For Mixed Shelf Of Up To $100 Million – SEC Filing
23rd Oct '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.